Sign in Subscribe
Cancer

Breakthrough in Cancer Therapy: Fucoidan-Chitosan Nanocarriers Show High Efficacy with Minimal Side Effects

Strategic Insights

— 1 min read

Researchers at Hanyang University have made a significant discovery in cancer therapy, developing fucoidan-chitosan nanocarriers that demonstrate high efficacy in reducing cancer cell viability while minimizing side effects. This innovative approach combines chemodynamic therapy, starvation therapy, and photothermal therapy to activate drug release and generate reactive oxygen species within the tumour microenvironment. The findings suggest that this nanocarrier system has the potential to be used in clinical biomedicine as a therapeutic platform with high efficacy and minimal side effects.

Key Takeaways:

  • The tumour microenvironment presents challenges and opportunities for targeted cancer therapies, and the developed fucoidan-chitosan nanocarrier system aims to reduce non-specific cell death and side effects on normal cells.
  • The nanocarrier, F/CS@TPGOx, loaded with 3,3',5,5'-tetramethylbenzidine (T), Prussian blue (P), and glucose oxidase (GOx), has been reported to reduce cancer cell viability to less than 20% following a four-hour incubation period.
  • The fucoidan in the nanocarrier system exhibits anticancer activity more pronounced than that observed in conventional anticancer nanocarriers.
  • The study demonstrated the efficacy of F/CS@TPGOx in cancer cell death in both in vitro and in vivo settings.
  • The findings suggest that F/CS@TPGOx has the potential to be used in clinical biomedicine as a therapeutic platform with high efficacy and minimal side effects.
  • The research has been peer-reviewed and published in Colloids and Surfaces B-biointerfaces.
  • The authors include Chang Hyeon Ha, Da Yeong Choi, Su Jeong Lee, and Gi Hun Seong.

Statistics:

  • Cancer cell viability reduction: less than 20% following a four-hour incubation period.
  • Concentration of F/CS@TPGOx: 4 g/mL.
  • Time period: four-hour incubation period.
  • Type of cancer therapy: chemodynamic therapy, starvation therapy, and photothermal therapy.
  • Type of nanocarrier: F/CS@TPGOx.
  • Efficacy: high efficacy with minimal side effects.

Sources:

  • Fucoidan-chitosan nanocarriers for anticancer therapy through chemodynamic, photothermal, and glucose starvation strategies. Colloids and Surfaces B-biointerfaces, 2025;253:114726.
  • Colloids and Surfaces B-biointerfaces. Publisher contact information: Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.
  • NewsRx. Hanyang University Reports Findings in Cancer (Fucoidan-chitosan nanocarriers for anticancer therapy through chemodynamic, photothermal, and glucose starvation strategies). Nanotechnology Weekly. May 12, 2025; p 397.

Read more